Synbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool

Reuters

Jan 15

Synbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool

Synbio International Inc. announced that it has signed a Master Services Agreement with CRO Services Pty Ltd, a subsidiary of Resonance Health Ltd. Under the agreement, CRO Services will conduct a proof-of-concept clinical trial in Australia to evaluate the efficacy of FacialDx Incorporated’s NIMS™ (Non-invasive Medical Screening) technology. The trial will assess the performance of the AI-powered facial analysis screening software for mental health disorders, such as Post-Traumatic Stress Disorder and Major Depressive Disorder, in real-world clinical conditions. The data from the study is intended to support future regulatory submissions and inform Synbio’s commercialization strategy in healthcare and corporate markets. The trial is expected to begin in early 2026, pending finalization of related agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Synbio International Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 1AXXF7E6y) on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603600986"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603600986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603600986?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603600986","market":"nz","top_or_hot":-1,"title":"Synbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Synbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SYIN\">Synbio International Inc. </a>announced that it has signed a Master Services Agreement with CRO Services Pty Ltd, a subsidiary of <a href=\"https://laohu8.com/S/RSHTF\">Resonance Health Ltd.</a> Under the agreement, CRO Services will conduct a proof-of-concept clinical trial in Australia to evaluate the efficacy of FacialDx Incorporated’s NIMS™ (Non-invasive Medical Screening) technology. The trial will assess the performance of the AI-powered facial analysis screening software for mental health disorders, such as Post-Traumatic Stress Disorder and Major Depressive Disorder, in real-world clinical conditions. The data from the study is intended to support future regulatory submissions and inform Synbio’s commercialization strategy in healthcare and corporate markets. The trial is expected to begin in early 2026, pending finalization of related agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Synbio International Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 1AXXF7E6y) on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Synbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSynbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Synbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SYIN\">Synbio International Inc. </a>announced that it has signed a Master Services Agreement with CRO Services Pty Ltd, a subsidiary of <a href=\"https://laohu8.com/S/RSHTF\">Resonance Health Ltd.</a> Under the agreement, CRO Services will conduct a proof-of-concept clinical trial in Australia to evaluate the efficacy of FacialDx Incorporated’s NIMS™ (Non-invasive Medical Screening) technology. The trial will assess the performance of the AI-powered facial analysis screening software for mental health disorders, such as Post-Traumatic Stress Disorder and Major Depressive Disorder, in real-world clinical conditions. The data from the study is intended to support future regulatory submissions and inform Synbio’s commercialization strategy in healthcare and corporate markets. The trial is expected to begin in early 2026, pending finalization of related agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Synbio International Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 1AXXF7E6y) on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909759.SGD","symbol_name":"Natixis Thematics Safety H-R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLc44Zj8:1","article_id":"2603600986","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603600986","pubTimestamp":1768482183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Synbio International Inc. announced that it has signed a Master Services Agreement with CRO Services Pty Ltd, a subsidiary of Resonance Health Ltd. Under the agreement, CRO Services will conduct a proof-of-concept clinical trial in Australia to evaluate the efficacy of FacialDx Incorporated’s NIMS  technology. The trial will assess the performance of the AI-powered facial analysis screening software for mental health disorders, such as Post-Traumatic Stress Disorder and Major Depressive Disorder, in real-world clinical conditions. The data from the study is intended to support future regulatory submissions and inform Synbio’s commercialization strategy in healthcare and corporate markets. The trial is expected to begin in early 2026, pending finalization of related agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909759.SGD":"Natixis Thematics Safety H-R/A SGD","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","BK5061":"环境与设施服务","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","LU1273509221.SGD":"Fidelity European Dynamic Growth A-ACC-SGD (hedged)","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1923622291.USD":"Natixis Thematics Safety R/A USD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1196032939.SGD":"Fidelity European Dynamic Growth A-SGD","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","RTO.UK":"能多洁","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK7007":"医疗保健设备","RHT.AU":"RESONANCE HEALTH LTD","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SYIN":"Synbio International Inc. "},"translate_title":"合生国际签署基于人工智能的精神健康筛查工具临床试验协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHT.AU":0.9,"RTO.UK":0.9,"SYIN":0.9},"content_text":"Synbio International Signs Agreement for Clinical Trial of AI-Based Mental Health Screening Tool\n    \n\nSynbio International Inc. announced that it has signed a Master Services Agreement with CRO Services Pty Ltd, a subsidiary of Resonance Health Ltd. Under the agreement, CRO Services will conduct a proof-of-concept clinical trial in Australia to evaluate the efficacy of FacialDx Incorporated’s NIMS™ (Non-invasive Medical Screening) technology. The trial will assess the performance of the AI-powered facial analysis screening software for mental health disorders, such as Post-Traumatic Stress Disorder and Major Depressive Disorder, in real-world clinical conditions. The data from the study is intended to support future regulatory submissions and inform Synbio’s commercialization strategy in healthcare and corporate markets. The trial is expected to begin in early 2026, pending finalization of related agreements.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Synbio International Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 1AXXF7E6y) on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}